SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing intense volatility and downward pressure as shareholders react to the sudden, immediate resignation of the CEO and uncertainty surrounding the leadership transition. While some investors are panic-selling, a segment of the community views the dip as a potential buying opportunity, pinning their thesis on upcoming updates regarding the Project Matador campus and potential interest from major AI data center tenants.

Maulcoin

Maulcoin is capturing attention as the community rallies around its unique 'Maul' identity while actively fending off copycat tokens and market volatility. Supporters are focusing on organic growth, long-term holding strategies, and transparency, viewing current price fluctuations as opportunities to reinforce their commitment to the project.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp. is capturing significant investor attention following a strong debut on the NYSE as market participants track the drone and automated defense systems sector. The community is actively debating the stock's momentum potential, weighing the company's growth narrative and recent media coverage against concerns regarding high volatility and institutional support.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as retail investors ramp up activity ahead of a highly anticipated data presentation at the AACR conference, fueling speculation about potential breakthroughs in cancer therapy. The community is actively debating the significance of the latest clinical trial developments, while heightened volume and ongoing battles between long-term supporters and short sellers continue to dominate the conversation.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is trending as investors capitalize on its strategic partnerships with industry giants like NVIDIA and its unique neutral-atom quantum technology. The community is actively debating the impact of upcoming share unlocks and potential short-squeeze dynamics, with many long-term holders highlighting the company's significant revenue growth and defense contracts as key differentiators within the quantum sector.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently driven by a bullish sentiment following a Goldman Sachs initiation with a significant price target, positioning the stock as a potential disruptor in the large-market atopic dermatitis space. While some community members are focused on a possible short squeeze and long-term acquisition potential due to its novel ITK inhibitor platform, others remain cautious regarding its early clinical stage, high volatility, and the risks associated with a crowded, competitive biotech landscape.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a long-standing satirical project from 2011 that has transitioned into a tokenized asset on the blockchain, sparking significant community debate. Supporters emphasize its deep historical roots and narrative authenticity, while discussions actively track whale accumulation, the project's defiance of market cycles, and its role as a polarizing symbol of crypto culture.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is gaining momentum as traders react to the elimination of pattern day trading (PDT) rules, with community members actively discussing a potential squeeze and comparing its growth trajectory to other fintech platforms. Investors are heavily focused on the stock's recent volatility and technical breakouts, with many pointing to the end of dilution concerns and anticipated increases in retail trading volume as key catalysts for continued upside.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is facing intense selling pressure as the market reacts to the release of Anthropic's 'Claude Design,' fueling concerns that generative AI will disrupt established SaaS design platforms. While the community remains deeply divided, with many debating if Figma is structurally threatened or merely experiencing a temporary pricing adjustment, others are actively scouting for a bottom amidst what they perceive as institutional manipulation and fear-based trading.

PolySwarm

PolySwarm ($NCT) is trending as investors monitor tight chart consolidation and low-float potential while anticipating a breakout driven by increased demand for decentralized cybersecurity threat intelligence. The community remains focused on active whale accumulation and the token's long-term utility, viewing current price levels as an entry point for an expected altcoin rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Jefferies had predicted that IOVA could see a 5%-15% move on Replime’s drug getting rejected.&nbsp;</li><li>According to Chardan analyst Geulah Livshits, RP1’s rejection is a positive for Iovance's Amtagvi's near-term competitive position.</li><li>Iovance story "remains centered on" Amtagvi's sales acceleration and margin expansion in 2026, according to Jefferies.</li></ul>Shares of Iovance Biotherapeutics Inc. (IOVA) garnered retail attention on Friday in light of an aspiring rival’s drug failing to get the nod from the U.S. Food and Drug Administration.IOVA shares closed down 8% on Friday, surprising retail investors and analysts alike. Jefferies had predicted that IOVA could see a 5%-15% move on Replimune’s drug getting rejected.Earlier on Friday, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">refused</a> to approve Replimune’s (REPL) investigational melanoma drug RP1. The agency said in a letter to the company that the data submitted by Replimune as part of its application seeking approval of the drug is “insufficient to conclude substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.Iovance’s Amtagvi cellular therapy is already approved as a treatment for people with previously treated melanoma that has spread or cannot be removed by surgery. The drug was granted accelerated approval in February 2024. The company recorded Amtagvi revenue of about $220 million for the full year 2025 in the U.S.<h2 class="st-heading-2">How Did Retail Traders React?</h2>A Stocktwits user expressed surprise at the stock closing down on the good news.<stembedurl>https://www.stocktwits.com/KingCuerv0/message/649991039</stembedurl>Yet another echoed the sentiment.<stembedurl>https://www.stocktwits.com/lebranjames/message/649990274</stembedurl>Another user opined that the stock may be down over concerns about FDA raising the bar for trials.<stembedurl>https://www.stocktwits.com/mlftt/message/649991395</stembedurl>Yet another user sounded optimism for clarity on sentiment around the stock on Monday. &nbsp;“Good news after good news lately, don’t let the price action tell you otherwise,” they said.<stembedurl>https://www.stocktwits.com/Morrito23/message/649985521</stembedurl>Overall retail sentiment around IOVA jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. Retail chatter around IOVA rose 75%, according to platform data.<h2 class="st-heading-2">Analyst Take</h2>According to data from Koyfin, eight of the 11 analysts covering IOVA rate it ‘Buy’ or higher, while three rate it ‘Hold’. There are no ‘Sell’ ratings of the stock.The average 12-month price target on the stock is $9, representing a potential upside of about 144%.According to Jefferies analyst Andrew Tsai, the rejection for RP1 means one less competitor for Iovance in the near term though Replimune was “technically not an overhang.” Iovance story "remains centered on" Amtagvi's sales acceleration and margin expansion in 2026, he said. The analyst has a ‘Buy’ rating and $12 price target on the shares.Chardan analyst Geulah Livshits also kept &nbsp;a ‘Buy’ rating on Iovance Biotherapeutics (IOVA) with a $16 price target after Replimune (REPL) update. RP1’s rejection is a positive for Iovance's Amtagvi's near-term competitive position, the analyst told investors in a research note. However, the firm added that more direct competition from cell therapies "could be on the horizon" in 2027.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> has gained 21% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cue-stock-on-track-for-best-day-in-history-why-is-retail-optimistic/cZJ0N5KRItC">CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why

Earlier on Friday, the FDA refused to approve Replimune’s investigational melanoma drug RP1, which was a likely contender for Iovance’s Amtagvi. 

Equity

Earlier on Friday, the FDA refused to approve Replimune’s investigational melanoma drug RP1, which was a likely contender for Iovance’s Amtagvi. 


Iovance Biotherapeutics' (IOVA) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued a "buy" rating and set a $16.00 target price on shares of Iovance Biotherapeutics in a report on Friday...

Promising Biotech Stocks To Follow Today - April 10th

Danaher, Vertex Pharmaceuticals, Iovance Biotherapeutics, argenex, and Moderna are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies whose primary business is developing, manufacturing, or commercializing bi...

Iovance Biotherapeutics (NASDAQ:IOVA)  Shares Down 6.6%   - Here's Why

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.6% - Should You Sell...

Investors Purchase High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders acquired 23,006 call options on the company. This is an...

Zacks Research Brokers Boost Earnings Estimates for IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at Zacks Research boosted their Q1 2026 EPS estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, April 8th. Zacks Research analyst Team now expects that the biotechnology company will earn...

<ul class="summary-bullets"><li>Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels.</li><li>Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product revenue in 2025.</li><li>RP1, in combination with Nivolumab, shrank tumors in about one-third of PD-1-failed melanoma patients.</li></ul>Shares of Replimune Group, Inc. (REPL) and Iovance Biotherapeutics, Inc. (IOVA) are back in focus on Friday ahead of an FDA decision on the former's lead immunotherapy candidate RP1, as investors compare a near-term approval catalyst with an already approved melanoma therapy.<a href="https://stocktwits.com/symbol/REPL">REPL stock</a> is on track for its worst weekly decline in nearly seven months after logging its biggest single-session drop in over six months on Wednesday. Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/IOVA">IOVA shares</a> are poised to snap a four-week losing streak after jumping 16% on Thursday, marking their best session in over a month.Koyfin estimates give Iovance the early lead on upside, but today’s RP1 verdict could determine whether Replimune closes the gap in a single catalyst move.<h2 class="st-heading-2">RP1 Decision Looms For Replimune</h2>Replimune’s lead candidate RP1, in combination with Nivolumab, an immunotherapy that helps the immune system attack cancer cells, is under U.S. Food and Drug Administration (FDA) review for patients with advanced melanoma whose disease has progressed after prior PD-1 therapy, with the Prescription Drug User Fee Act (PDUFA) decision due Friday.The company’s commercial readiness activities are already underway to support the launch if approval is granted. Trial results from last year showed that RP1 combined with Nivolumab shrank tumors in about one-third of patients whose melanoma had already stopped responding to standard PD-1 immunotherapy, including complete tumor disappearance in 15% of patients.Consensus estimates tracked by Koyfin place Replimune’s average price target at $12.86, implying a 116% upside from current levels. The stock is covered by seven analysts, with one rating it ‘Strong Buy’, four ‘Buy’, and two ‘Hold’, resulting in an overall consensus rating of ‘Strong Buy’.Several analysts turned bullish after the FDA accepted the BLA resubmission in October. H.C. Wainwright raised its probability of approval to 85% from 50%, while Piper Sandler expects a potential mid-2026 launch. JPMorgan added that the “totality of the RP1 data in the refractory melanoma setting is compelling and warrants approval.”<h2 class="st-heading-2">Amtagvi Gives Iovance Commercial Edge</h2>Unlike Replimune, Iovance already has an approved therapy on the market. The FDA approved Amtagvi in 2024 as the first therapy made from a patient’s own tumor-fighting immune cells for people with advanced melanoma that cannot be removed with surgery or has spread after earlier PD-1 immunotherapy stopped working.The company reported $264 million in total product revenue in 2025, including $220 million from Amtagvi, marking its first full calendar year of launch. The company flagged increasing treatment-center adoption and manufacturing improvements expected to continue this year.Consensus estimates place Iovance’s average analyst price target at $9, representing a 124% upside from the stock’s last close. The stock is covered by 11 analysts, with two rating it ‘Strong Buy’, six ‘Buy’, and three ‘Hold’, supporting a consensus rating of ‘Strong Buy’.Iovance is also expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform into several cancers beyond melanoma. Updated data in February showed that 44% of melanoma patients responded to Amtagvi, while additional trials are underway in non-small-cell lung cancer, sarcoma and frontline melanoma combinations. The FDA has also granted Fast Track designation to Amtagvi in advanced non-small-cell lung cancer.<h2 class="st-heading-2">How Do Retail Traders Feel About REPL, IOVA?</h2>On Stocktwits, retail sentiment for REPL was ‘bearish’ amid ‘extremely high’ message volume, while sentiment toward IOVA was ‘bullish’ amid ‘high’ message volume.One user&nbsp;<a href="https://stocktwits.com/Bob_Whitley/message/649897269">warned</a> that approval appeared unlikely ahead of the decision, saying "Take off the blinders, the stock [REPL] tanked this week on no news, IOVA had a surge, the trial design was basically picked apart at the joints in the last CRL."<stembedurl>https://stocktwits.com/Bob_Whitley/message/649897269</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/RunnersOnly4/message/649889153">said</a>, “Why gamble with REPL when you have a sure thing with IOVA at a lower price?”<stembedurl>https://stocktwits.com/RunnersOnly4/message/649889153</stembedurl>Over the past year, shares of REPL have fallen 19%, while IOVA stock has risen 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-dips-hk-after-es9-debut-what-went-wrong/cZJ0cCeRIsD">Nio Stock Dips In HK After ES9 Debut: What Went Wrong?</a>

Over the past year, shares of REPL have fallen 19%, while IOVA stock has risen 23%. (Photo credit: Getty Images)

REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays

REPL stock is heading for its worst weekly loss in nearly seven months ahead of the FDA decision on RP1.

<ul class="summary-bullets"><li>FDA is slated to decide on potential rival Replimune’s application for RP1 in the treatment of advanced melanoma by April 10.</li><li>Iovance’s Amtagvi cellular therapy is already approved as a treatment for people with previously treated melanoma that has spread or cannot be removed by surgery.</li><li>The company recorded Amtagvi revenue of about $220 million for the full year 2025 in the U.S.</li></ul> Shares of Iovance Biotherapeutics (IOVA) closed up 16% on Thursday as investors await the U.S. Food and Drug Administration’s decision on its aspiring competitor Replimune’s (REPL) skin cancer drug.IOVA stock has closed in the green for three consecutive days and recorded its best single-day gain on Thursday since late February.The FDA is slated to decide on Replimune’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.Iovance’s Amtagvi cellular therapy is already approved as a treatment for people with previously treated melanoma that has spread or cannot be removed by surgery. The drug was granted accelerated approval in February 2024. &nbsp;The company recorded Amtagvi revenue of about $220 million for the full year 2025 in the U.S.<h2 class="st-heading-2">Retail Chimes In</h2>A Stocktwits user said that rejection for Replimune’s drug will be the “end of the last anchor” holding IOVA down.<stembedurl>https://www.stocktwits.com/EvrytIsNothingWithaTwist/message/649873087</stembedurl>Another expressed anticipation for the decision.<stembedurl>https://www.stocktwits.com/medinapj/message/649874467</stembedurl><h2 class="st-heading-2">RP1’s Past Issues</h2>In late July 2025, the FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, Replimune subsequently resubmitted its application in October with additional information, data, and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around IOVA stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.Meanwhile, sentiment around REPL trended in ‘extremely bearish’ territory at the time of writing. &nbsp;<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> has gained 23% over the past 12 months while <a href="https://stocktwits.com/symbol/REPL">REPL stock</a> fell 19%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-gemi-stock-up-eleven-percent/cZJWX2VRIsh">GEMI Stock On Track To Record Best Session In Over A Month On Acquisition Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IOVA Stock Clocks Best Session Since February As Retail Awaits FDA Decision On Rival Drug

IOVA stock closed in the green for the past three days and recorded its best single-day gain on Thursday since late February.

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 7.1% - Time to Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.1% Higher - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving Average - Here's What Happened

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Crosses Below 50 Day Moving Average - Here's What Happened...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IOVA News

IOVAIovance Biotherapeutics Inc